Lisata Therapeutics Inc
LSTA
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.97M
Close$
$1.85
86.2% upside
Current Fair Value
86.2% upsideUndervalued by 86.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.97 Million |
|---|---|
| Enterprise Value | $-1,469,005.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.91 |
| Beta | 0.8 |
| Outstanding Shares | 9,106,000 |
Return
| Return on Equity | -177.35% |
|---|---|
| Return on Assets | -132.59% |
| Return on Invested Capital | -61.47% |
Valuation & Multiples
| P/E Ratio | -0.61 |
|---|---|
| PEG | 1.64 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -14.69 |
| Enterprise Value to EBIT | 0.3 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-1.13
Average shareholder expectationRevenue Estimate
$659,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 13.27%▼ 3.10% |
|---|---|
| Total Invested | $4.11M▼ 42.08% |
| Investors Holding | 31▼ 4.00% |
ESG Score
No data
About Lisata Therapeutics Inc
24 employees
CEO: David Mazzo Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely tuned mec...